Category - Markets

Markets

Stifel starts AdaptHealth at buy; PT $17

Stifel initiated coverage of AdaptHealth (NASDAQ:AHCO) with a “buy” rating and $17 price target. The stock closed at a 52-week high of $13 on Jan. 30. “AdaptHealth is a unique asset poised to capitalize on an ongoing...

January 31, 2020

Markets

HCW cuts Iterum Therapeutics PT to $9 from $14

H.C. Wainwright lowered its price target for Iterum Therapeutics (NASDAQ:ITRM) to $9 from $14 after the company unveiled a $52-million private placement of exchangeable and royalty-linked subordinated notes earlier this...

January 31, 2020

Markets

Roth sees Hepion completing transition into NASH company in 2020

Hepion Pharmaceuticals (NASDAQ:HEPA) is poised to make the final stages of its transition into a company focused on non-alcoholic steatohepatitis (NASH) in 2020 with two key catalysts that will show off the potentially...

January 29, 2020

Markets

Raymond James ups Profound Medical to strong buy; PT to $45 from $35

Raymond James upgraded Profound Medical (TSX:PRN; NADAQ:PROF) to “strong buy” from “outperform” and raised its price target to $45 (Canadian) from $35, selecting Profound as its “2020 Best Pick.” Shares of Profound...

January 28, 2020

Markets

BTIG starts Cue Biopharma at buy; PT $26

BTIG launched coverage of Cue Biopharma (NASDAQ:CUE) with a “buy” rating and $26 price target. The stock closed at $15.51 on Jan. 27. Cue Biopharma exploits signals naturally provided by dendritic cells (DCs) to...

January 28, 2020

Markets

Dawson James ups CollPlant PT to $15 from $9

Dawson James Securities raised its price target for CollPlant Biotechnologies (NASDAQ:CLGN) to $15 from $9, reflecting an “increase in valuation, which translates into less dilution in terms of our assumptions around...

January 27, 2020

Markets

Raymond James starts Cardiol Therapeutics at OP 2; PT $5

Raymond James launched coverage of Cardiol Therapeutics (TSX:CRDL) with an “outperform 2” rating and price target of $5 (Canadian). The stock closed $4 on Jan.23. Cardiol’s therapeutic strategy is focused around the...

January 24, 2020

Markets

AGP ups Itamar Medical PT to $19.50 from $15.50

Alliance Global Partners raised its price target for Itamar Medical (NASDAQ:ITMR) to $19.50 from $15.50, reflecting preliminary fourth quarter revenue results, 2020 guidance and a recent meeting with the company’s...

January 22, 2020

Markets

Ladenburg starts ArTara Therapeutics at buy; PT $45

Ladenburg Thalmann initiated coverage of ArTara Therapeutics (NASDAQ:TARA) with a “buy” rating and $45 price target. The stock closed at $28.34 on Jan. 21. ArTara has two late-stage clinical assets in development for...

January 22, 2020

Markets

Echelon starts Protech Home Medical at buy; PT $2.50

Echelon Wealth Partners launched overage of Protech Home Medical (TSXV:PTQ) with a “buy” rating and price target of $2.50. The stock closed at 91 cents on Jan. 22. “We believe the firm is well positioned within [the...

January 22, 2020

Category - Markets

Stifel starts AdaptHealth at buy; PT $17

HCW cuts Iterum Therapeutics PT to $9 from $14

Roth sees Hepion completing transition into NASH company in 2020

Raymond James ups Profound Medical to strong buy; PT to $45 from $35

BTIG starts Cue Biopharma at buy; PT $26

Dawson James ups CollPlant PT to $15 from $9

Raymond James starts Cardiol Therapeutics at OP 2; PT $5

AGP ups Itamar Medical PT to $19.50 from $15.50

Ladenburg starts ArTara Therapeutics at buy; PT $45

Echelon starts Protech Home Medical at buy; PT $2.50

Follow Us

General

More

Subscribe